NVN Liquidation Past Earnings Performance
Past criteria checks 0/6
NVN Liquidation has been growing earnings at an average annual rate of 6.1%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 512.7% per year.
Key information
6.1%
Earnings growth rate
29.0%
EPS growth rate
Pharmaceuticals Industry Growth | 14.1% |
Revenue growth rate | 512.7% |
Return on equity | n/a |
Net Margin | -128.6% |
Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How NVN Liquidation makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 23 | 25 | -32 | 38 | 0 |
31 Dec 22 | 24 | -31 | 34 | 0 |
30 Sep 22 | 14 | -37 | 31 | 0 |
30 Jun 22 | 9 | -37 | 26 | 0 |
31 Mar 22 | 4 | -34 | 16 | 0 |
31 Dec 21 | 3 | -30 | 12 | 0 |
30 Sep 21 | 3 | -28 | 11 | 0 |
30 Jun 21 | 4 | -30 | 11 | 0 |
31 Mar 21 | 5 | -32 | 11 | 0 |
31 Dec 20 | 5 | -29 | 11 | 0 |
30 Sep 20 | 5 | -29 | 11 | 3 |
30 Jun 20 | 5 | -30 | 10 | 7 |
31 Mar 20 | 5 | -30 | 10 | 11 |
31 Dec 19 | 5 | -30 | 10 | 15 |
30 Sep 19 | 8 | -17 | 11 | 15 |
30 Jun 19 | 7 | -15 | 12 | 15 |
31 Mar 19 | 6 | -14 | 12 | 15 |
31 Dec 18 | 6 | -13 | 12 | 15 |
30 Sep 18 | 3 | -28 | 11 | 15 |
30 Jun 18 | 3 | -28 | 11 | 15 |
31 Mar 18 | 3 | -30 | 12 | 11 |
31 Dec 17 | 3 | -37 | 13 | 14 |
30 Sep 17 | 2 | -42 | 14 | 13 |
30 Jun 17 | 1 | -52 | 14 | 11 |
31 Mar 17 | 0 | -60 | 14 | 13 |
31 Dec 16 | 0 | -60 | 13 | 9 |
30 Sep 16 | 0 | -57 | 13 | 8 |
30 Jun 16 | 0 | -45 | 13 | 7 |
31 Mar 16 | 0 | -32 | 11 | 6 |
31 Dec 15 | 0 | -26 | 9 | 5 |
30 Sep 15 | -3 | -21 | 7 | 2 |
31 Dec 14 | 0 | -13 | 5 | 2 |
31 Dec 13 | 3 | -6 | 4 | 3 |
Quality Earnings: 0A4P is currently unprofitable.
Growing Profit Margin: 0A4P is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 0A4P's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 0A4P's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0A4P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: 0A4P's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.